08th week of 2010 patent applcation highlights part 42 |
Patent application number | Title | Published |
20100047216 | COMPOSITIONS OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS) - The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and/or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker. | 2010-02-25 |
20100047217 | DIFFERENTIATED ANUCLEATED CELLS AND METHOD FOR PREPARING THE SAME - Provided herein are methods for preparing differentiated cells, and the cells prepared by such methods. | 2010-02-25 |
20100047218 | REVERSIBLE IMMORTALIZATION - A gene complex for reversibly immortalizing cells contains an immortalizing gene region, which possesses at least a resistance gene, an immortalizing gene and, preferably, a suicide gene, and also two sequences which flank the gene region and which function as recognition sites for homologous intramolecular recombination, and at least one promoter located upstream of the gene region. A gene complex for immunomodulating cells contains a first immunomodulating gene region, whose expression inhibits the function of MHC I molecules, a second immunomodulating gene region, whose expression leads to the inactivation of natural killer cells, and a resistance gene. A method for obtaining cells involves preparing organ-related cells which are immortalized by transferring the first gene complex and immunomodulated by transferring the second gene complex. After the immortalized cells have been expanded, the immortalization is reversed. | 2010-02-25 |
20100047219 | MARINE EXTRACTS AND BIOFERMENTATIONS FOR USE IN COSMETICS - An extract of the marine algae, | 2010-02-25 |
20100047220 | Substances - This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs. | 2010-02-25 |
20100047221 | COMPOSITIONS COMPRISING PYRUVATE ALKYL ESTERS AND USES THEREOF - The present invention provides a composition comprising pyruvic acid alkyl ester for ingestion by a human as a food, oral supplement or pharmaceutical. | 2010-02-25 |
20100047222 | Nucleic acids and polypeptides of C1 bacteriophage and uses thereof - The full-length nucleic acid sequence of the C | 2010-02-25 |
20100047223 | Pharmanutrient Composition(s) and System(s) for Individualized, Responsive Dosing Regimens - Individualized responsive dosing pharmanutrient systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a pharmanutrient system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, organics substrates, inorganic or synthetic substrates, biological components, and/or other nutrients incorporated or provided with a pharmacologically active ingredient in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different pharmanutrient based on varying desired biological response within each dosing period. | 2010-02-25 |
20100047224 | Biosilica-Adhesive Protein Nanocomposite Materials: Synthesis and Application in Dentistry - The invention concerns the application of silicatein-silk fibroin fusion proteins in dentistry to synthesize silica-containing nanocomposite materials used as filling material. | 2010-02-25 |
20100047225 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 2010-02-25 |
20100047226 | COMPOSITIONS AND METHODS FOR INHIBITING TUMOR CELL GROWTH - The present invention relates to compositions and methods for inhibiting the activity of an enzyme, for example, Protein Kinase B, p70S6K and/or Abl using the catalytic subunit of Protein Kinase A (PKAc), or at least one PKAc fragment or variant PKAc fragment thereof. In this regard, methods for preventing or treating cancer or a neurodegenerative disease or disorder are also provided. | 2010-02-25 |
20100047227 | NOVEL ANTICANCER CATHEPSIN FORMULATIONS AND ANTICANCER AGENT FOR USE IN COMBINED ANTICANCER THERAPY - An anticancer cathepsin preparation contains, as the active ingredient, cathepsin E and/or an active fragment consisting of the active site thereof or containing the active site thereof. The anticancer cathepsin preparation inhibits the growth of cancer cells alone and prevents the metastasis thereof without exerting any undesirable effect on normal cells. Moreover, it can induce apoptosis in cancer cells. When used in combination with another anticancer agent, it can potentiate the sensitivity thereof, even to a cancer to which the existing anticancer agent shows no sensitivity. Owing to the sensitivity potentiating effect, the therapeutic effect on cancer can be remarkably enhanced. By potentiating the sensitivity of the anticancer agent, furthermore, the dose of the anticancer agent per se can be decreased and, in its turn, the side effects, etc. of the anticancer agent can be largely reduced. | 2010-02-25 |
20100047228 | RECOMBINANTLY MODIFIED PLASMIN - Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme. | 2010-02-25 |
20100047229 | PURIFIED RECOMBINANT BATROXOBIN WITH HIGH SPECIFIC ACTIVITY - A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32 kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys | 2010-02-25 |
20100047230 | ANTI HER2/NEU ANTIBODY - The present invention describes an isolated antibody or a fragment, variant or derivative thereof, capable of specifically binding to Her2/neu comprising a heavy chain variable domain wherein said heavy chain variable domain comprises an amino acid sequence as set out in at least one of SEQ ID NOs: 1, 2 or 3 or a sequence having at least 75% identity (homology) thereto or a functional fragment thereof as well as nucleic acid sequences encoding the same and methods for their production. The invention also relates to a method for the treatment of Her2/neu expressing cancer in a patient comprising administering to the patient in need of such treatment a therapeutically effective amount of any of those antibody, polypeptide or nucleic acid molecules described herein. | 2010-02-25 |
20100047231 | Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C - The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus. | 2010-02-25 |
20100047232 | MODULATORS OF NEURONAL REGENERATION - The present invention provides methods and compositions related to CNS function and diseases. | 2010-02-25 |
20100047233 | TREATMENT OF POST-MENOPAUSAL AND POST-HYSTERECTOMY MEDIATED COGNITIVE DISORDERS - A method of treating or preventing post-menopausal or post-hysterectomy related cognitive decline in a subject includes administering to the subject a therapeutically effective amount of at least one physiologically acceptable non-estrogenic agent that reduces or eliminates gonadotropin and/or gonadotropin receptor levels in the subject. | 2010-02-25 |
20100047234 | TREATING SKIN CANCER - This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided. | 2010-02-25 |
20100047235 | NOVEL REGIMENS FOR TREATING DISEASES AND DISORDERS - Methods and materials are provided for induction-maintenance regimens of targeted anti-inflammatory therapies (TATs) for treatment of a variety of diseases and disorders. Preferred embodiments include administration of one or more TATs using an induction regimen comprising a lower dose per administration administered by a more invasive and/or more localized route, followed by administration of one or more TATS using a maintenance regimen, comprising a higher dose per administration administered by a less invasive and/or less localized route. | 2010-02-25 |
20100047236 | ANTIBODY VARIANTS - Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen. | 2010-02-25 |
20100047237 | PREVENTION OF AGGREGATION OF IMMUNOGLOBULIN LIGHT OR HEAVY CHAINS - The present invention provides an inhibitor of the aggregation of immunoglobulin chains (or immunoglobulin V | 2010-02-25 |
20100047238 | HUMANIZED ANTIBODIES AGAINST - Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function. | 2010-02-25 |
20100047239 | Dual variable domain immunoglobulin and uses thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 2010-02-25 |
20100047240 | Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors - Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena. | 2010-02-25 |
20100047241 | FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF - The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering. | 2010-02-25 |
20100047242 | PHARMACEUTICAL COMPOSITIONS CAPABLE OF INDUCING APOPTOSIS IN TUMOUR CELLS, USEFUL FOR DIAGNOSIS AND TREATMENT OF B-CHRONIC LYMPHOCYTIC LEUKAEMIA - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology. | 2010-02-25 |
20100047243 | NOVEL ANTIBODIES AGAINST IGF-IR - The present invention relates to antibodies or antigen binding fragments thereof which specifically binds to IGF-1R, specifically hIGF-1R. Also disclosed are antibody preparations comprising antibodies or antigen binding fragments of the invention. Methods of producing such antibodies or antigen binding fragments and uses thereof are also included within the scope of the present invention. | 2010-02-25 |
20100047244 | Human CTLA-4 Antibodies and Their Uses - The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. | 2010-02-25 |
20100047245 | IL-12/P40 BINDING PROTEINS - The present invention encompasses IL-12 | 2010-02-25 |
20100047246 | Methods and Compositions for Treating Vascular Disease - This invention relates to compositions and methods for use in treating or preventing vascular disease, as well as diseases and conditions associated with hematopoiesis and cellular proliferation. | 2010-02-25 |
20100047247 | NERVE ELONGATION PROMOTER AND ELONGATION INHIBITOR - The invention provides agents that promote or inhibit neurite elongation comprising as an active ingredient an antibody that recognizes a varicella-zoster virus immediate-early protein and cross-reacts with a brain-derived neurotrophic factor. The invention also provides methods of utilizing such agents to prevent or treat a nervous disease or a disease with nerve hypersensitivity caused by a condition selected from the group consisting of postherpetic neuralgia, chronic pains, experience-dependent social aversion and stress. | 2010-02-25 |
20100047248 | METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES - A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, providing one or more non-solvents comprising an aqueous solution containing at least one multivalent cation, exposing the multi-phasic dispersion to the non-solvent to form a suspension containing one or more liquid phases and the solid microparticles, and removing at least a portion of the resulting one or more liquid phases while retaining at least the microparticles, thereby removing at least a portion of the non-volatile material from the microparticles. | 2010-02-25 |
20100047249 | INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS - The invention relates to pharmaceutical compositions for inhibiting FcγR-mediated phagocytosis comprising a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis, such as anti-D, in combination with a pharmaceutically acceptable carrier. The invention also relates to methods for treating or preventing an autoimmune or alloimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis. | 2010-02-25 |
20100047250 | ACTIVATION EPITOPE OF FCY RII (CD32), BINDING MOLECULES THAT SPECIFICALLY BIND THE EPITOPE AND MEANS AND METHODS FOR THE DETECTION OF THE EPITOPE, AND USES OF SAID EPITOPE OR SAID BINDING MOLECULES - The present invention provides means and method for detecting an activation epitope on FcyRII (CD32) on Fcγ (CD32) expressing cells. The presence of epitope on FcγRII (CD32) correlates with priming of the cell containing FcγRII (CD32) expressing said epitope. The invention further provides binding molecules specific for said activation epitope on FcγRII (CD32), and uses thereof in the detection of activated cells. Further uses are the treatment of individuals suffering from inflammation or at risk of suffering thereof. Also provided, among others, are uses for detecting and/or following an inflammation in an individual. | 2010-02-25 |
20100047251 | ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USE THEREOF - The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases. | 2010-02-25 |
20100047252 | ANTIBODY WITH PROTEIN A SELECTIVITY - Monoclonal antibodies, and antigen binding fragments thereof, which bind to Protein A of | 2010-02-25 |
20100047253 | FULLY HUMAN MONOCLONAL ANTIBODIES TO IL-13 - The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided. | 2010-02-25 |
20100047254 | High Affinity Human Antibodies to Human IL-4 Receptor - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 2010-02-25 |
20100047255 | NOVEL ACTIVATION AND TRANSFER CASCADE FOR UBIQUITIN - A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided. | 2010-02-25 |
20100047256 | METHODS - The present invention relates to methods of diagnosing, prognosing, preventing or delaying onset of or treating rheumatoid arthritis, methods of distinguishing between different types or stages of rheumatoid arthritis, of identifying an individual at risk of developing rheumatoid arthritis, and of monitoring efficacy of a treatment regime in an individual being treated for rheumatoid arthritis, using a citrullinated enolase peptide to detect or capture antibodies associated with rheumatoid arthritis. | 2010-02-25 |
20100047257 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors. | 2010-02-25 |
20100047258 | Drug Carriers, Their Synthesis, and Methods of Use Thereof - Drug carriers, methods of synthesizing, and methods of use thereof are provided. | 2010-02-25 |
20100047259 | FOLLISTATIN DOMAIN CONTAINING PROTEINS - The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration. | 2010-02-25 |
20100047260 | Methods and Compositions Relating To a Vaccine Against Prostate Cancer - An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e.g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen. | 2010-02-25 |
20100047261 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN - The present application describes a base-modified RNA and the use thereof for increasing the expression of a protein and for the preparation of a pharmaceutical composition, especially a vaccine, for the treatment of tumours and cancer diseases, heart and circulatory diseases, infectious diseases, autoimmune diseases or monogenetic diseases, for example in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the base-modified RNA, and an in vivo method. | 2010-02-25 |
20100047262 | NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID - Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous APP or Aβ, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations. | 2010-02-25 |
20100047263 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide or a functionally active variant of the protective peptide; a composition comprising at least two proteins selected from the group consisting of i) a first type of protective peptide or functionally active variant thereof, ii) a second type of protective peptide or functionally active variant thereof and iii) a supportive peptide or a functionally active variant thereof; one or more nucleic acid(s) encoding the protective peptide or functionally active variant thereof or the at least two proteins comprised in the composition; a pharmaceutical composition comprising the protective peptide or functionally active variant thereof, the composition, or the nucleic acid(s); a method of producing an antibody using the protective peptide or functionally active variant thereof or the composition; the use of the protective peptide or functionally active variant thereof and/or the composition and/or the nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; a method of diagnosing a | 2010-02-25 |
20100047264 | Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof - An affinity-conjugated antigen system (ACAS) comprising one or more antigens conjugated via a plurality of affinity moieties to a papaya mosaic virus (PapMV) or virus-like particle (VLP) derived from the coat protein of PapMV is provided. The affinity moieties are molecules or compounds that are capable of specifically binding to the antigen(s) of interest and which can be attached, for example by chemical or genetic means, to the coat protein of the PapMV or PapMV VLP. The ACAS can optionally further comprise one or more additional antigens, which may be the same as, or different to, the conjugated antigen(s) comprised by the ACAS. Also provided are immunogenic compositions, including vaccines, comprising an ACAS. The immunogenic compositions are useful in the treatment, including prevention, of various diseases and disorders for which a humoral and/or cellular response in the animal is required. | 2010-02-25 |
20100047265 | ACTIVE ANTIANGIOGENIC THERAPY - Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. | 2010-02-25 |
20100047266 | CHIMERIC VIRUS-LIKE PARTICLES - Chimeric virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide and lipid raft-associated polypeptide linked to an antigen that is not naturally associated with a lipid raft. Preferred methods of generation include expression in insect cells. | 2010-02-25 |
20100047267 | Staphylococcus aureus proteins and nucleic acids - The invention provides proteins from | 2010-02-25 |
20100047268 | FUSION PROTEINS OF HIV REGULATORY/ACCESSORY PROTEINS - The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections. | 2010-02-25 |
20100047269 | Strain Of Turkey Tail Mushroom, Extract From The Same, And Use Of The Same - The present invention provides a new strain of turkey tail mushroom ( | 2010-02-25 |
20100047270 | USE OF PLANT CELL MEMBRANE FOR THE TREATMENT OF OBESITY - Use of a composition comprising cell membrane, or hydrophobic peptides derived from said cell membrane, for the reduction of lipolytic activity, retardation of fat digestion, suppression of appetite, decrease of body weight and/or lowering of blood lipids. Satiety for fat is mainly driven from the intestine. By the contact of fat with the intestinal mucosa, various satiety peptides are released, thus suppressing appetite and food intake. A reduced rate of fat digestion could optimise the satiety for fat, through prolonged release of satiety peptides. Fat digestion can be retarded by reduction of the lipolytic activity of pancreatic lipase. The examples show that fractions of plant cell membranes (thylakoids) inhibit the lipolytic activity of pancreatic lipase. | 2010-02-25 |
20100047271 | VACCINE COMPOSITIONS - The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen, wherein the charged antigen is a polyprotein of Hepatitis C Virus (HCV), particularly the core protein of HCV, or a fragment thereof, or a fusion protein comprising the polyprotein or a fragment thereof. The complexes of the present invention are useful, inter alia, in vaccine compositions as therapeutic and/or prophylactic agents for facilitating the induction of immune responses, and in particular a cytotoxic T-lymphocyte response, in the treatment of a disease condition which results from an HCV infection. | 2010-02-25 |
20100047272 | Therapeutic vaccine comprising mycobacterial heat shock protein 70 - The present invention relates to the use of a mycobacterial heat-shock protein for the manufacture of a vaccine for therapeutic application. | 2010-02-25 |
20100047273 | Coxsackie B virus and type 1 diabetes - Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis. | 2010-02-25 |
20100047274 | INOCULATION OF RECOMBINANT VIRAL VECTORS FOR RAPID PRE-EXPOSURE PREVENTION AND POST-EXPOSURE PROTECTION AGAINST ALPHA-VIRUS-INDUCED ENCEPHALITIDES - This invention addresses how to rapidly prevent alphavirus-induced encephalitides before and after exposure to alphaviruses. The invention discloses a single dose administration of two types of recombinant viral vectors: one expressing interferon and another expressing the structural proteins of alphaviruses or a single dose administration of the recombinant viral vector co-expressing both interferon and the structural proteins of alphaviruses. This invention can be used to prevent humans from alphavirus-induced encephalitides in the event of a bioterrorism attack or biowarfare in which alphaviruses such as Venezuelan (VEEV), eastern (EEEV) and western (WEEV) equine encephalitis viruses are deliberately released to humans, a natural outbreak of alphaviruses, and an accidental exposure to alphaviruses in laboratory. | 2010-02-25 |
20100047275 | PEPTIDE SEQUENCES AND COMPOSITIONS - Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: | 2010-02-25 |
20100047276 | Recombinant Vectors Based On the Modified Vaccinia Ankara Virus (MVA) as Preventive and Therapeutic Vaccines Against Aids - Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses object of the invention contain sequences which are inserted at the same MVA insertion site and which enable the simultaneous expression of various antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. Said viruses are stable and can trigger immune responses against a large variety of antigens. Those viruses having a chimeric protein that derives from sequences of HIV-1 are suitable for the preparation of preventative or therapeutic vaccines against AIDS, particularly for use as vaccination protocols comprising various doses and different vectors, as demonstrated by assays performed using other vectors from the invention, having the same genome organization, but a chimeric protein that derives from sequences of pathogenic SHIV | 2010-02-25 |
20100047277 | VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS - Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one viral surface envelope glycoprotein expressed on the surface of the virosome. The virosome can also optionally include at least one adjuvant molecule expressed on the surface of the virosome. | 2010-02-25 |
20100047278 | Human Rotavirus and Vaccine Composition Comprising Same - Provided are G12 human rotaviruses having VP7 gene of SEQ ID NO: 1 or 2 and VP4 gene of SEQ ID NO: 3 or 4; antibodies specific for said rotaviruses; and a vaccine composition containing the same. The antibodies and the vaccine composition are effective for diagnosing rotavirus infection and for treatment of diseases caused by rotavirus. | 2010-02-25 |
20100047279 | IMMUNOLOGICAL COMPOSITION - The present invention relates to immunological compositions comprising sulpholipo-cyclodextrin (SL-CD) and, saponin or Quil A, and optionally at least one antigen. The invention relates to methods and immunological compositions comprising at least one antigen, which may be a veterinary antigen. The veterinary antigen in the methods and immunological compositions of the invention may be a bovine antigen. The invention relates to methods and immunological compositions comprising bovine ephemeral fever virus (BEFV), bovine herpesvirus 1 (IBR) or bluetongue virus (BTV). The invention comprises methods for eliciting an immune response against BEFV, IBR, or BTV in an animal, which comprises administering to the animal a composition of the invention. In the invention, particularly the immune response is a protective immune response. The invention comprises a method for preparing an immunological composition comprising adding Quil A to a virus. | 2010-02-25 |
20100047280 | FLAVIVIRUS NS1 SUBUNIT VACCINE - The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1. | 2010-02-25 |
20100047281 | VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other antagonists of HBV DNA polymerase activity and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants. These assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular the resistant HBV variants of the present invention. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus. | 2010-02-25 |
20100047282 | METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES - The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form. | 2010-02-25 |
20100047283 | FRANCISELLA STRAIN FOR LIVE VACCINE - A strain of | 2010-02-25 |
20100047284 | METHOD FOR REDUCING SPASMS COMPRISING TREATMENT WITH AN AGENT THAT ELEVATES THE LEVEL OF ONE OR MORE CYCLIC NUCLEOTIDES IN THE MUSCLE - This invention relates to methods for preventing or reducing spasms in smooth muscle, using an agent that elevates the level of one or more nucleotide in the muscle, or an agent which comprises a toxin. The invention also relates to the use of such agents in the manufacture of a medicament for preventing or reducing spasms in smooth muscle. | 2010-02-25 |
20100047285 | ANTICANCER AGENTS USING VEROTOXIN VARIANTS - An attenuated verotoxin comprising a verotoxin A subunit amino acid sequence in which at least one of the amino acids at positions 167 to 172 and positions 202 to 207 from the N terminus is mutated; an attenuated verotoxin A subunit thereof; a complex of the A subunit with a ligand; an anticancer agent using the verotoxin, A subunit or ligand; a method for treating cancer; a gene that encodes the attenuated verotoxin or its A subunit; a gene therapy agent using the gene; and a gene therapy method. | 2010-02-25 |
20100047286 | Recombinant BCG strains with enhanced ability to escape the endosome - strains that have an enhanced ability to elicit a Histocompatibility-Class I-restricted CD8 | 2010-02-25 |
20100047287 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 2010-02-25 |
20100047288 | Hybrid cells for treating cancer patients - The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation. | 2010-02-25 |
20100047289 | UNIVERSAL TUMOR CELL VACCINE FOR ANTI CANCER THERAPEUTIC AND PROPHYLACTIC UTILIZATION - The invention provides a composition for stimulating an immune response in a patient having different types of cancer including those having adenocarcinoma comprising a combination of allogeneic tumor cells and/or tumor stem cells that are selected on the basis of secreting at least one immunosuppressive agent, e.g., TGF-β, and that are genetically modified to reduce or inhibit the expression of said at least one immunosuppressive agent, e.g., TGF-β, and that collectively express a spectrum of tumor associated antigens representative of colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, and other glandular tissue carcinomas, as well as squamous, melanoma, central nervous system, and lymphomas and a physiologically acceptable carrier. The adenocarcinoma can be, for example, colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, or other glandular tissue, as well as squamous, melanoma, central nervous system, and lymphomas. The invention also provides a composition containing said combination of allogeneic tumor cells and or tumor stem cells and an allogeneic cell expressing a cytokme or an antibody that inhibits an immune suppressive molecule. | 2010-02-25 |
20100047290 | FUNCTIONAL PROTEIN CRYSTALS CONTAINING A CORE NANO-PARTICLE AND USES THEREOF - A functional protein crystal, wherein each protein in the crystal comprises a cavity containing a core nano-particle, the core nano-particle formed from an elemental metal, a metal alloy, or a metal compound, with the proviso that the protein is not apoferritin Dpr or | 2010-02-25 |
20100047291 | COSMETIC FORMULATIONS WITH IR PROTECTION - The present invention relates to cosmetic formulations with IR protection which are distinguished by the fact that they comprise functional pigments. The invention furthermore relates to cosmetic formulations which, besides the IR pigment, comprise colorants, fillers, cosmetic active compounds and cosmetic raw materials and auxiliaries, and to the use thereof in care and decorative cosmetics. | 2010-02-25 |
20100047292 | METHODS OF PROCESSING MICROPARTICLES AND COMPOSITIONS PRODUCED THEREBY - A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, positioning the multi-phasic dispersion within a chamber capable of being pressurized, pressurizing the chamber with a first gas to a pressure less than the supercritical pressure of the gas, and contacting the multi-phasic dispersion with the first gas. | 2010-02-25 |
20100047293 | FRAGRANCE EMITTING PATCH - The present invention relates to a fragrance emitting patch that a user can attach to the body or an article of clothing, and more particularly to a fragrance emitting patch having a configuration that permits the easy application and removal of the fragrance emitting patch by a user. | 2010-02-25 |
20100047294 | SEMI-FINISHED PRODUCT IN THE MANUFACTURE OF A COMPOSITION FOR SKIN OR HAIR CARE - A semi-finished product is manufactured from raw liquid, extract or powder obtained from wood material, an end product composition for skin or hair care being obtained from the semi-finished product by adding one or more components thereto. The semi-finished product optionally contains a UV protector, and is a liquid, emulsion, microemulsion or nanoemulsion or a dispersion, suspension, wax, lotion or gel or a solid substance. The semi-finished product further contains an active ingredient mixture which contains phenolic compounds having antioxidative and/or microbicidal properties and/or abilities to capture free radicals. The active ingredient mixture contains as phenolic compounds at least one oligolignan, and at least two lignans, tannins or flavonoids selected from a group consisting of hydroxymatairesinol, matairesinol, oxomatairesinol, lariciresinol, cyclolariciresinol, secoisolariciresinol nortrachelogenin, pinoresinol, pinosylvine, conidendrine, melacasidine, teracasidine, ellaga-tannin or a reaction product, stereoisomer or derivative of these compounds. | 2010-02-25 |
20100047295 | SKIN CARE COMPOSITION - Skin care emulsion compositions are disclosed comprising an oil-in-water emulsion comprising phospholipid-stabilized, submicron triglyceride particles, botanical material selected from the group consisting of a vegetal material, a marine material and combinations thereof; a polycarboxylate polymer and a phosphate ester-type emulsifier. The skin care compositions can be topically applied to the skin before, and surprisingly, together with, and/or after applying a skin colorant (i.e., pigmented) cosmetic composition to moisturize the skin and achieve, augment, and/or maintain a visibly desirable cosmetic appearance. | 2010-02-25 |
20100047296 | Low-Residue Cosmetic Or Dermatological Stick Based On An Oil-In-Water Dispersion/Emulsion III - Cosmetic or dermatological sticks, especially deodorant or antiperspirant sticks, based on an oil-in-water dispersion/emulsion to be applied to the skin. | 2010-02-25 |
20100047297 | NANOCRYSTALS FOR USE IN TOPICAL COSMETIC FORMULATIONS AND METHOD OF PRODUCTION THEREOF - Provided are cosmetic preparations for topical application containing nanocrystals of cosmetic actives leading to an increased bioactivity of the molecules in the skin and methods of making the cosmetic preparations. The nanocrystals can be added to any cosmetic topical formulation, e. g. creams, lotions and liposomal dispersions. The drug nanocrystals are produced by a combination process of low energy pearl milling followed by a high energy high-pressure homogenization leading to nanocrystal suspensions (nanosuspensions) of improved physical stability. | 2010-02-25 |
20100047298 | PROCESS FOR TREATING THE SKIN BY APPLYING SILICONE COMPOUNDS - The invention relates to a cosmetic treatment method for improving the superficial appearance of the skin, and especially for reducing the visible and/or tactile irregularities of the skin, such as cutaneous microrelief. According to said method, a filling product is applied to the irregularities, said product resulting from a hydrosilylation reaction, in the presence of a catalyst, between two compounds X and Y, at least one of said compounds being a silicone compound, and both compounds being brought into contact with each other in the presence of a catalyst such that the reaction occurs at least partially on the skin. | 2010-02-25 |
20100047299 | USE OF GDF-5 FOR THE IMPROVEMENT OR MAINTENANCE OF DERMAL APPEARANCE - The present invention is directed to novel methods and compositions containing growth factor proteins. Said compositions are specifically designed to optimize the amount of crucial structural elements of mammalian tissues. The invention is especially useful for the preservation and improvement of dermal tissue appearance. | 2010-02-25 |
20100047300 | PEARLESCENT PIGMENTS CONTAINING COSMETIC COMPOSITIONS - The present invention is directed to a cosmetic composition comprising an effect pigment based on a glass flake as a substrate with a coating, said coating comprising at least one layer of at least one high refractive material, said material having a refractive index of at least 1.8, and/or a semitransparent metal coating wherein said glass flakes comprising the following composition: 65-75 wt.-% silicon oxide, preferably SiO | 2010-02-25 |
20100047301 | Dry Nail Polish Applique Delivery System - A nail appliqué product for delivering nail additives to a fingernail. The appliqué has an adhesive layer that, in use, is in direct contact with a wearer's fingernail. The adhesive layer contains additives such as vitamins, minerals and/or drugs that are delivered to a fingernail after the appliqué is affixed thereto. The appliqué is flexible and conformable to a fingernail and it continues to deliver additive for an extended period of time. | 2010-02-25 |
20100047302 | ANTIMICROBIAL FOOD PACKAGING - The present invention relates to a single or multi layered food packaging on the basis of plastics wherein the layer or at least one of the layers comprises at least one metal with antimicrobial activity and wherein at least part of the metal with antimicrobial activity is present in finely divided metallic form and the remaining part is present in form of a salt. | 2010-02-25 |
20100047303 | ABSORBENT ARTICLES COMPRISING AN ORGANIC ZINC SALT AND AN ANTI-BACTERIAL AGENT OR ALKALI METAL CHLORIDE OR ALKALINE EARTH METAL CHLORIDE - An absorbent article, such as a diaper, panty diaper, sanitary napkin or incontinence device includes a topsheet, a backsheet and an absorbent core enclosed between the topsheet and the backsheet. The absorbent core includes an anti-bacterial agent or an alkali metal or alkaline earth metal chloride in combination with an organic zinc salt, in particular, zinc ricinoleate. The combination of antibacterial or (earth) alkali metal chloride and organic zinc salt exerts a synergetic effect in the suppression of malodours, such as ammonia. | 2010-02-25 |
20100047304 | Anti-biocontaminant Products and Processes for Making the Same - The present invention relates to micro-sized particles having anti-biocontaminant properties. Each particle is comprised of a central metal core, or support structure, (for example, alumina oxide) and has on its surface, one or more anti-biocontaminant metals and at least one redox agent. | 2010-02-25 |
20100047305 | Extracellular Matrix Compositions - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications. | 2010-02-25 |
20100047306 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES - The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers. The depot formulation may be in the form of microparticles or implants. The depot formulations are useful for the treatment and prevention of proliferative diseases including cancer. | 2010-02-25 |
20100047307 | INJECTABLE DRUG CARRIER COMPRISING LAYERED DOUBLE HYDROXIDE - Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug. | 2010-02-25 |
20100047308 | Production methods of virus inactivated and cell-free body implant - A method is provided for producing a virus-inactivated, acellular implant for the human body, featuring the use of TNBP in combination with a detergent selected from among deoxycholate, SDS, Tween 80, Triton X-100, sodium cholate and combinations thereof for removing cells and viruses simultaneously. Also disclosed are an acellular human body implant produced by the method and a wound healing agent comprising the acellular human body implant. | 2010-02-25 |
20100047309 | Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods - This application describes apparatuses and methods for musculoskeletal tissue engineering. Specifically, graft collar and scaffold apparatuses are provided for promoting fixation of musculoskeletal soft tissue to bone. | 2010-02-25 |
20100047310 | Bio-acceptable conduits and method providing the same - Disclosed is a bio-electrospinning technique for preparing a cell-containing, oriented, continuous tubular scaffold, made of biodegradable polymer, designed for use as a nerve guide conduit (NGC) in nerve regeneration. With a coaxial spinneret, the PC-12 cell medium solution was co-electrospun into a core of tubular fibers, with PLA on the outer shell. The resulted fibers' morphology was characterized via SEM and optical microscopy, and following structural characteristics were found: 1. the larger, hollow fibers had diameters in tenth of microns and wall thicknesses around few microns, 2. an orientation in a preferred direction with the aid of a high-rotating collection device. The fluorescent PC12 cells embedded within the scaffold were cultured and nerve growth factor was added. We observed cells could not only survive the process, but also sustain their viability by undergoing differentiation process, extending neurite along the micro tubular scaffold in the desired direction. All these results demonstrate its potential application for advanced NGC. | 2010-02-25 |
20100047311 | PROTECTING ALGAE FROM BODY FLUIDS - Apparatus ( | 2010-02-25 |
20100047312 | USE OF BIOACTIVE AND RADIOPAQUE MATERIAL FOR STENT COATING - The invention relates to a stent having a coating or cavity filling comprising or containing an organic Au complex. | 2010-02-25 |
20100047313 | MEDICAL DEVICES HAVING A COATING FOR ELECTROMAGNETICALLY-CONTROLLED RELEASE OF THERAPEUTIC AGENTS - Medical devices having a coating comprising an ionic polymer for electromagnetically-controlled release of a therapeutic agent. Release of the therapeutic agent from the coating is facilitated or modulated by the application of an electromagnetic field to the medical device. Exposure to the electromagnetic field may cause the release of the therapeutic agent in various ways, including electrochemical changes in the ionic polymer, structural changes in the coating and/or ionic polymers, changes in the permeability of the coating, changes in the orientation of the ionic polymers, or motion of the ionic polymers. Also disclosed are methods for delivering a therapeutic agent using electromagnetic fields. | 2010-02-25 |
20100047314 | FOLINIC ACID DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-02-25 |
20100047315 | Stent for Increasing Blood Flow to Ischemic Tissues and a Method of Using the Same - Stents and a method of using the stents to increase blood flow to ischemic tissues in a patient are disclosed. | 2010-02-25 |